Nominations for the 2014 award are now closed.
Learn more about the inaugural award recepient, Dr. James P. Allison
The AACR-CRI Lloyd J. Old Award in Cancer Immunology was established to honor the memory of the late Lloyd J. Old and will recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.
The recipient of the award will receive an honorarium of $10,000, give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, Calif. (April 5-9, 2014), and will be provided support for the winner and a guest to attend the AACR Annual Meeting 2014.
- The award is open to all cancer immunologists who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry, or government.
- Candidates will be considered on the basis of their highly significant and innovative research, the impact of these discoveries on the cancer field, and the stimulation of new directions in cancer immunology. All areas of cancer immunology will be considered for this award.
- Candidates must currently maintain an active research program, have a record of recent publications, and be able to present an exciting award lecture at the annual meeting.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nomination Procedure and Instructions
Nominations may be made by any scientist, whether an AACR member on nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science. Candidates may not nominate themselves.
Nominations must be emailed to email@example.com by 4 p.m. United States Eastern Time on Friday, Sept. 6, 2013. Paper nominations will not be accepted.
Nomination materials to be submitted are:
1) Nomination Letter. The letter must:
- be addressed to the Selection Committee, be written in English, and not exceed 1,000 words;
- specify the AACR award for which the candidate is being nominated;
- contain a concise description of the candidate's highly significant and innovative research, and the stimulation of new directions in cancer immunology, with the publications supporting these accomplishments directly referenced within the letter;
- contain a concise description of the impact of these accomplishments in the cancer field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Candidates will be considered by an Award Selection Committee composed of members nominated by both the Cancer Research Institute and the AACR. After careful deliberation by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award recipient will be made on the basis of the candidate's scientific accomplishments without regard to race, gender, nationality, geographic location, or religious or political views.
Generously supported by the Cancer Research Institute.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
Inaugural Award Recipient
James P. Allison, Ph.D.
Chairman, Immunology Program
UT MD Anderson Cancer Center
Dr. Allison delivered his award lecture titled Mobilizing the Immune System for Cancer Therapy
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Wednesday, April 10, 2013, from 10:00 a.m.-11:00 a.m. Visit the AACR Annual Meeting 2013
page to learn more about the Annual Meeting.
Dr. Allison has laid the foundation for our ability to manipulate the T cell system for therapeutic applications against cancers, and is therefore greatly deserving of this honor.
In 1982, Dr. Allison and his colleagues identified the T cell antigen receptor (TCR), which recognizes foreign antigens. He also discovered that this recognition is not sufficient for the activation of naïve T cells. Subsequently, he discovered two key molecules, the CD28, which is constitutively expressed on the surface of the T cell and is needed for its activation, and a homolog of CD28 called CTLA-4, which is induced after the activation of the T cell, and is a major down-regulator of T cells. Dr. Allison described how all these molecules act in concert in the process of engaging the antigen presenting cells that carry the foreign antigens, such as cancer antigens.
Dr. Allison hypothesized that the immune system fails to recognize tumor cells since CTLA-4 down-regulates T cell activation. Based on this theory, he created antibodies to this molecule and demonstrated the rejection of established tumors in several mouse model systems. He then developed an antibody to human CTLA-4, ipilimumab, which has been used in clinical trials in more than 4,000 patients with a variety of cancers including metastatic melanoma, prostate, renal, lung and ovarian cancers. A randomized blinded phase 3 trial with metastatic melanoma resulted in the survival of 25 percent of the patients for 4 years. No other drug has shown a prolongation of life in similar trials for this disease. Ipilimumab was approved by the U.S. Food and Drug Administration in 2011.
In recent years, Dr. Allison identified several other checkpoint and costimulatory molecules and he has been testing the combination of immunological therapies and targeted therapies such as tyrosine kinase inhibitors, for more effective treatment against cancers. He will play an instrumental role in MD Anderson's recently announced Moon Shots Program to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.
Allison earned his bachelor's degree in microbiology and his doctorate in biological sciences from The University of Texas at Austin. After a postdoctoral fellowship at Scripps Clinic and Research Foundation in California, Allison took a faculty position at MD Anderson's Science Park - Research Division in Smithville, Texas. Allison next moved to the University of California, Berkeley, where he was a professor in the Division of Immunology and director of the Cancer Research Laboratory. He then moved to Memorial Sloan-Kettering in 2004. Recently, Dr. Allison moved back to MD Anderson Cancer Center to chair the Department of Immunology.